Piribedil Enhances Frontocortical and Hippocampal Release of Acetylcholine in Freely Moving Rats by Blockade of α2A-Adrenoceptors: A Dialysis Comparison to Talipexole and Quinelorane in the Absence of Acetylcholinesterase Inhibitors

@article{Gobert2003PiribedilEF,
  title={Piribedil Enhances Frontocortical and Hippocampal Release of Acetylcholine in Freely Moving Rats by Blockade of $\alpha$2A-Adrenoceptors: A Dialysis Comparison to Talipexole and Quinelorane in the Absence of Acetylcholinesterase Inhibitors},
  author={Alain P. Gobert and Benjamin di Cara and Laetitia Cistarelli and Mark J Millan},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2003},
  volume={305},
  pages={338 - 346}
}
In a dialysis procedure not requiring perfusate addition of acetylcholinesterase inhibitors to “boost” basal levels of acetylcholine (ACh), the influence of the antiparkinson agent piribedil upon levels of ACh in frontal cortex and dorsal hippocampus of freely moving rats was compared with those of other antiparkinson drugs and selective ligands at α2-adrenoceptors (ARs). Suggesting a tonic, inhibitory influence of α2A-ARs upon cholinergic transmission, the α2-AR agonist 5-bromo-6-[2-imidazolin… 

Figures and Tables from this paper

The Serotonin1A Receptor Partial Agonist S15535 [4-(Benzodioxan-5-yl)1-(indan-2-yl)piperazine] Enhances Cholinergic Transmission and Cognitive Function in Rodents: A Combined Neurochemical and Behavioral Analysis
TLDR
S15535 reinforces frontocortical and hippocampal release of acetylcholine and displays a broad-based pattern of procognitive properties, which are consistent with previous work on cholinergic transmission and cognitive function in rodents.
Selective blockade of dopamine D3 versus D2 receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis
TLDR
Selective blockade of D3 receptors facilitates frontocortical cholinergic transmission and improves social memory in rats, and support the pertinence of D 3 receptors as a target for treatment of disorders in which cognitive function is compromised.
S32212, a Novel Serotonin Type 2C Receptor Inverse Agonist/α2-Adrenoceptor Antagonist and Potential Antidepressant: II. A Behavioral, Neurochemical, and Electrophysiological Characterization
TLDR
The present studies characterized the functional profile of S32212, a combined serotonin (5-HT)2C receptor inverse agonist and α2-adrenoceptor antagonist that also possesses 5-HT2A antagonist properties that displays a functional profile consistent with improved mood and cognitive performance, together with satisfactory tolerance.
Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors
The dopamine D2/D3 receptor agonist and &agr;2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of
S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2 Receptors: II. Actions in Rodent, Primate, and Cellular Models of Antiparkinsonian Activity in Comparison to Ropinirole
TLDR
S32504 displays potent and stereospecific activity in rodent, primate, and cellular models of antiparkinsonian properties and engagement of D3 receptors contributes to its neuroprotective properties.
Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats.
TLDR
D1 receptors exert a tonic, facilitatory influence upon cholinergic transmission and social recognition within freely moving rats and underpin the relevance of D1 receptors to CNS disorders in whichCholinergic Transmission and social cognition are disrupted.
Trace Amine-Associated Receptor 1 Contributes to Diverse Functional Actions of O-Phenyl-Iodotyramine in Mice but Not to the Effects of Monoamine-Based Antidepressants
TLDR
O-PIT is a useful tool for exploring the hypothermic and other functional antidepressant roles of TAAR1, and by contrast, clinically used antidepressants do not require TAar1 for expression of their antidepressant properties.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 64 REFERENCES
Multiple alpha-2 adrenergic receptor subtypes. II. Evidence for a role of rat R alpha-2A adrenergic receptors in the control of nociception, motor behavior and hippocampal synthesis of noradrenaline.
TLDR
A correlation matrix was constructed and revealed a strong correlation among the tests and allowed for a comparison between drug potency in inhibiting these alpha-2 AR-mediated actions and affinity at various populations of alpha-1 adrenergic receptor subtypes.
Acetylcholine Release in the Rat Prefrontal Cortex In Vivo: Modulation by α2‐Adrenoceptor Agonists and Antagonists
TLDR
Results indicate a modulatory role for α2‐adrenoceptors on the release of ACh in the rat prefrontal cortex in vivo and suggest a therapeutic usefulness in disorders where cortical ACh release deficits have been implicated.
Modulation of cortical acetylcholine and gamma-aminobutyric acid release in freely moving guinea pigs: effects of clonidine and other adrenergic drugs.
TLDR
The present experiments indicate that the neurochemical and neuropharmacological profile of activity of clonidine is strictly dependent upon the dose of the drug, and support the concept that cortical alpha adrenoceptors modulate the function of neurons releasing ACh or GABA.
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
TLDR
The antiparkinsonian agent piribedil displays essentially antagonist properties at cloned, human and cerebral, rat alpha(2)-ARs and weakly induced mitogen-activated protein kinase phosphorylation via wild-type halpha(2A-ARs, although attenuating its phosphorylated by NE.
Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo.
TLDR
The data suggest that a combination of cholinergic and adrenergic drug may improve the pharmacological effect of the cholinesterase inhibitor on cortical neurotransmitters such as ACh-NE, and that such a combination does not represent an advantage as a therapeutical alternative for treatment of cognitive impairment in Alzheimer disease patients.
Characterization of Central Inhibitory Muscarinic Autoreceptors by the Use of Muscarinic Acetylcholine Receptor Knock-Out Mice
TLDR
Release studies with brain slices from M2 and M4 receptor single KO mice indicated that autoinhibition of ACh release is mediated primarily by the M2 receptor in hippocampus and cerebral cortex, but predominantly by theM4 receptor in the striatum.
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor
TLDR
In conclusion, antiparkinson agents display diverse agonist and antagonist properties at multiple subtypes of D2-like receptor and α1/α2-AR, actions, which likely contribute to their contrasting functional profiles.
Effects of acute and subchronic administration of dexefaroxan, an alpha(2)-adrenoceptor antagonist, on memory performance in young adult and aged rodents.
TLDR
A potential utility of dexefaroxan in the treatment of cognitive deficits occurring in Alzheimer's disease is supported, by appearing to have a promnesic effect in these tests by facilitating the processes of memory retention, rather than acquisition or other noncognitive influences.
...
1
2
3
4
5
...